Christine Terré

6.4k total citations
59 papers, 1.9k citations indexed

About

Christine Terré is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Christine Terré has authored 59 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Hematology, 22 papers in Molecular Biology and 21 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Christine Terré's work include Acute Myeloid Leukemia Research (46 papers), Acute Lymphoblastic Leukemia research (21 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Christine Terré is often cited by papers focused on Acute Myeloid Leukemia Research (46 papers), Acute Lymphoblastic Leukemia research (21 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Christine Terré collaborates with scholars based in France, United States and Belgium. Christine Terré's co-authors include Sylvie Castaigné, Hervé Dombret, Claude Preudhomme, Claude Gardin, Cécile Pautas, Xavier Thomas, Pascal Turlure, Thierry de Revel, Emmanuel Raffoux and Dominique Bordessoule and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Christine Terré

57 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christine Terré France	20	1.6k	770	579	448	393	59	1.9k
Hartmut Doehner Germany	9	1.9k 1.2×	806 1.0×	572 1.0×	606 1.4×	402 1.0×	32	2.2k
Erin P. Demakos United States	10	1.4k 0.9×	1.0k 1.3×	474 0.8×	275 0.6×	219 0.6×	31	1.9k
Ya‐Zhen Qin China	23	1.5k 1.0×	503 0.7×	472 0.8×	639 1.4×	305 0.8×	153	1.9k
Stephen E. Langabeer Ireland	20	2.3k 1.4×	1.3k 1.7×	959 1.7×	584 1.3×	251 0.6×	104	2.7k
S Chatters United Kingdom	6	1.3k 0.8×	521 0.7×	382 0.7×	416 0.9×	154 0.4×	8	1.4k
Andrea Corbacioglu Germany	9	2.4k 1.5×	1.3k 1.7×	863 1.5×	708 1.6×	182 0.5×	21	2.7k
Giovanna Rege‐Cambrin Italy	21	1.4k 0.9×	612 0.8×	893 1.5×	669 1.5×	293 0.7×	70	2.0k
Joseph O. Moore United States	10	1.0k 0.7×	555 0.7×	368 0.6×	350 0.8×	181 0.5×	17	1.3k
Brenton G. Mar United States	16	1.5k 1.0×	982 1.3×	667 1.2×	279 0.6×	260 0.7×	33	2.3k
Marianne Habdank Germany	9	2.3k 1.5×	1.3k 1.7×	895 1.5×	612 1.4×	213 0.5×	17	2.7k

Countries citing papers authored by Christine Terré

Since Specialization

Citations

This map shows the geographic impact of Christine Terré's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Terré with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Terré more than expected).

Fields of papers citing papers by Christine Terré

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Terré. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Terré. The network helps show where Christine Terré may publish in the future.

Co-authorship network of co-authors of Christine Terré

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Terré. A scholar is included among the top collaborators of Christine Terré based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Terré. Christine Terré is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guermouche, Hélène, Benoît Quilichini, Christine Terré, et al.. (2025). Deciphering Genomic Complexity of Multiple Myeloma Using Optimized Optical Genome Mapping. Journal of Molecular Diagnostics. 27(4). 306–322. 2 indexed citations

Hirsch, Pierre, Jérôme Lambert, Maxime Bucci, et al.. (2024). Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study. Blood Cancer Journal. 14(1). 97–97. 3 indexed citations

Duployez, Nicolas, Juliette Lambert, Maël Heiblig, et al.. (2023). Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML. Blood. 142(Supplement 1). 4322–4322.

Nguyen‐Khac, Florence, Audrey Bidet, Agnès Daudignon, et al.. (2022). The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia. 36(6). 1451–1466. 17 indexed citations

Lapillonne, Hélène, Meyling Cheok, Claude Preudhomme, et al.. (2022). Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study. Blood Advances. 6(9). 2773–2777. 5 indexed citations

Lambert, Juliette, Cécile Pautas, Christine Terré, et al.. (2018). Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 104(1). 113–119. 237 indexed citations

Smol, Thomas, Annika Dufour, Sabine Tricot, et al.. (2017). Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma. Molecular Cytogenetics. 10(1). 26–26. 13 indexed citations

Luquet, Isabelle, Audrey Bidet, Wendy Cuccuini, et al.. (2016). Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH). Annales de biologie clinique. 74(5). 535–546. 5 indexed citations

Smol, Thomas, Olivier Nibourel, Alice Marceau‐Renaut, et al.. (2015). Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research. 39(12). 1443–1447. 9 indexed citations

10.

Lambert, Juliette, Jérôme Lambert, Olivier Nibourel, et al.. (2014). MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 5(15). 6280–6288. 59 indexed citations

11.

Castaigné, Sylvie, Cécile Pautas, Christine Terré, et al.. (2014). Final Analysis of the ALFA 0701 Study. Blood. 124(21). 376–376. 17 indexed citations

12.

Lambert, Juliette, Jérôme Lambert, Olivier Nibourel, et al.. (2012). Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin. Blood. 120(21). 659–659. 5 indexed citations

13.

Thomas, Xavier, Sylvie Castaigné, Emmanuel Raffoux, et al.. (2012). Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow Transplantation. 47(11). 1436–1441. 9 indexed citations

14.

Itzykson, Raphaël, Claude Gardin, Cécile Pautas, et al.. (2011). Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica. 96(6). 837–844. 16 indexed citations

15.

Pautas, Cécile, Fatiha Merabet, Xavier Thomas, et al.. (2010). Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. Journal of Clinical Oncology. 28(5). 808–814. 164 indexed citations

16.

Thomas, Xavier, Sylvie Castaigné, Emmanuel Raffoux, et al.. (2010). Long-Term Outcome Associated with Current Allogeneic Stem Cell Transplantation Procedures In Younger Adults with Adverse-Risk AML In First CR – A Real-Life Transplant Versus No-Transplant Analysis of the Acute Leukemia French Association (ALFA). Blood. 116(21). 3513–3513. 1 indexed citations

17.

Thomas, Xavier, Emmanuel Raffoux, Aline Renneville, et al.. (2010). Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study. Cancer. 116(7). 1725–1732. 16 indexed citations

18.

Richebourg, Steven, Virginie Éclache, Christine Pérot, et al.. (2008). Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genetics and Cytogenetics. 182(2). 95–102. 33 indexed citations

19.

Prébet, Thomas, Nicolas Boissel, Christian Récher, et al.. (2008). Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML Intergroup. Blood. 112(11). 553–553. 1 indexed citations

20.

Turlure, Pascal, Claude Gardin, Jean‐Valère Malfuson, et al.. (2006). Impact of Post-Remission Therapy on Survival of Older Patients with AML Treated with Intensive Chemotherapy: Results of the Multicenter ALFA-9803 Trial.. Blood. 108(11). 421–421. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact